- Home
- MDCX vs HBIO Comparison
MDCX vs HBIO Comparison
Compare MDCX & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDCX | HBIO |
|---|---|---|
| Founded | 2008 | 1901 |
| Country | United States | United States |
| Employees | 16 | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.6M | 26.5M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | MDCX | HBIO |
|---|---|---|
| Price | $0.40 | $6.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $14.50 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 1.1M | 10.7K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $116,176,000.00 |
| Revenue This Year | N/A | $4.77 |
| Revenue Next Year | N/A | $8.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.25 | $0.38 |
| 52 Week High | $3.05 | $7.50 |
Technical Indicators
Market Signals| Indicator | MDCX | HBIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.10 | 49.27 |
| Support Level | $0.37 | $6.05 |
| Resistance Level | $0.50 | $6.70 |
| Average True Range (ATR) | 0.04 | 0.26 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 56.72 | 21.95 |
Price Performance
Historical ComparisonAbout MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.